<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431518</url>
  </required_header>
  <id_info>
    <org_study_id>ViiV Healthcare IIS 1837</org_study_id>
    <nct_id>NCT04431518</nct_id>
  </id_info>
  <brief_title>PK of JULUCA in Hemodialysis</brief_title>
  <official_title>The Steady-State Pharmacokinetics of Dolutegravir/Rilpivirine Fixed Dose Combination (FDC) in Patients With End Stage Renal Disease (ESRD) Requiring Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the pharmacokinetics of the component drugs in JULUCA, and HIV&#xD;
      combination treatment pill, in HIV-negative patients who require hemodialysis with those with&#xD;
      normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics of dolutegravir and rilpivirine, the components of JULUCA, in patients&#xD;
      with end stage renal disease requiring hemodialysis have not previously been adequately&#xD;
      studied. It is possible that the PK of these drugs are affected by renal failure which may&#xD;
      then compromise effectiveness and safety. This trial will rigorously assess the plasma PK and&#xD;
      protein-binding of these two drugs in 10 HIV-negative patients requiring hemodialysis with 10&#xD;
      matched persons with normal renal function. All participants will receive JULUCA for up to 14&#xD;
      days and then undergo a 24 hour intensive PK evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Matched case-control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DTG Ctau</measure>
    <time_frame>11-14 days</time_frame>
    <description>Steady-state plasma Ctau for dolutegravir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RPV Ctau</measure>
    <time_frame>11-14 days</time_frame>
    <description>Steady-state plasma Ctau for rilpivirine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DTG and RPV AUC</measure>
    <time_frame>11-14 days</time_frame>
    <description>Steady-state plasma AUC for dolutegravir and rilpivirine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DTG and RPV Cmax</measure>
    <time_frame>11-14 days</time_frame>
    <description>Steady-stage plasma Cmax for dolutegravir and rilpivirine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>Hemodialysis Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receipt of JULUCA one pill per day up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Renal Function Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receipt of JULUCA one pill per day up to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JULUCA 50Mg-25Mg Tablet</intervention_name>
    <description>One dose of JULUCA will be taken daily for up to 14 days</description>
    <arm_group_label>Hemodialysis Group</arm_group_label>
    <arm_group_label>Normal Renal Function Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Negative HIV antibody testing at screening.&#xD;
&#xD;
          2. For the ESRD requiring HD study group: ESRD requiring chronic hemodialysis for at&#xD;
             least 6 months at an established center (not home dialysis).&#xD;
&#xD;
             NOTE: The approximate date that hemodialysis was initiated should be reported, if&#xD;
             known.&#xD;
&#xD;
             For the normal renal function group: Estimated CrCl (using the Cockcroft-Gault&#xD;
             equation) at screening &gt;90mL/min.&#xD;
&#xD;
          3. Availability of alternative venous access (not used for dialysis) for the purpose of&#xD;
             PK sampling.&#xD;
&#xD;
          4. The following laboratory values obtained within 30 days prior to study entry (obtained&#xD;
             either at screening or done as part of routine clinical care):&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) less than or equal to ULN&#xD;
&#xD;
               -  Total bilirubin less than or equal to 1.5 x ULN&#xD;
&#xD;
               -  Hemoglobin greater than or equal to 8.0 mg/dL&#xD;
&#xD;
          5. A negative serum pregnancy test result at screening for all women of reproductive&#xD;
             potential who have not reached menopause or undergone hysterectomy, bilateral&#xD;
             oophorectomy, or tubal ligation.&#xD;
&#xD;
          6. Males and females, age 18-65 years.&#xD;
&#xD;
          7. Ability and willingness of participant or legal guardian/representative to provide&#xD;
             written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or hypersensitivity to either dolutegravir or rilpivirine&#xD;
&#xD;
          2. Use of peritoneal dialysis.&#xD;
&#xD;
          3. Serious illnesses, other than ESRD, requiring systemic treatment and/or&#xD;
             hospitalization within 30 days prior to the Screening Visit.&#xD;
&#xD;
          4. Known liver cirrhosis, unstable liver disease (presence of ascites, encephalopathy,&#xD;
             coagulopathy, esophageal/gastric varices), Child-Pugh Class A, B, or C, or known&#xD;
             biliary abnormalities (except for known Gilbert's syndrome or asymptomatic&#xD;
             gallstones).&#xD;
&#xD;
          5. Hepatitis B surface antigen or hepatitis C antibody with detectable RNA at screening.&#xD;
&#xD;
          6. Known gastrointestinal disease that may lead to poor absorption of the study drugs.&#xD;
&#xD;
          7. Known hereditary problems of galactose intolerance, total lactase deficiency, or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
          8. Any of the following gastrointestinal signs or symptoms of Grade ≥ 2 within 7 days&#xD;
             prior to the Screening Visit or during study drug administration prior to the&#xD;
             Intensive PK Study Visit:&#xD;
&#xD;
               -  nausea&#xD;
&#xD;
               -  vomiting&#xD;
&#xD;
               -  diarrhea&#xD;
&#xD;
               -  abdominal pain&#xD;
&#xD;
          9. Use of any of the following within 30 days of initiating study drug:&#xD;
&#xD;
               -  Medications known to appreciably inhibit or induce CYP3A enzymes, P-glycoprotein,&#xD;
                  or UGT1A1 or UGT1A4 enzymes (e.g., anticonvulsants such as carbamazepine,&#xD;
                  phenytoin, oxacarbamazepine; antimycobacterials such as rifampin, rifabutin and&#xD;
                  rifapentine; antifungal agents such as ketoconazole, fluconazole and&#xD;
                  itraconazole; verapamil, clarithromycin, erythromycin)&#xD;
&#xD;
               -  St. John's Wort, echinacea, grapefruits or grapefruit juice, garlic supplements,&#xD;
                  ginseng, golden seal, and milk thistle&#xD;
&#xD;
               -  Cancer chemotherapeutic agents&#xD;
&#xD;
               -  Investigational agents&#xD;
&#xD;
               -  Immunomodulators, including systemic steroids greater than or equal to 100 mg/day&#xD;
                  of prednisone (Note: Topical and inhaled corticosteroids are allowed.)&#xD;
&#xD;
               -  Dofetilide&#xD;
&#xD;
               -  Positive pre-study drug screen. Drugs that will be screened for include&#xD;
                  amphetamines, barbiturates, cocaine and phencyclidine (PCP). Active injected drug&#xD;
                  users will be excluded from this study.&#xD;
&#xD;
         10. Use of proton pump inhibitors within 7 days of initiating study drug (H2 blockers are&#xD;
             permitted).&#xD;
&#xD;
         11. Pregnancy and/or breast-feeding.&#xD;
&#xD;
         12. Moderate to severe depression, defined as a PHQ-9 ≥ 10 at Screening.&#xD;
&#xD;
         13. Significant change (i.e., more than a 50% change) in tobacco smoking habit within 6&#xD;
             weeks prior to the Screening Visit. Participants who have recently stopped smoking&#xD;
             should have stopped smoking more than 6 weeks prior to the Screening Visit.&#xD;
             Participants who have recently started smoking should have started more than 6 weeks&#xD;
             prior to the Screening Visit.&#xD;
&#xD;
         14. QTc interval greater than 500 msec at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir K Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samir K Gupta, MD</last_name>
    <phone>317-274-7926</phone>
    <email>sgupta1@iu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samir Gupta</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Gupta</last_name>
      <phone>317-274-7926</phone>
      <email>sgupta1@iu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samir K Gupta, MD, MS</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>ESRD</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir, rilpivirine drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD will provided upon request and approval by the investigators or through online data repositories such as Figshare.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>IPD will become available after publication of the data, anticipated to be by July 2022.</ipd_time_frame>
    <ipd_access_criteria>Fully available when posted to online repositories. Additional data upon request and approval by the study investigators. The financial sponsor will not have a role in this process.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT04431518/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 18, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT04431518/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

